2021 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant Recipients Treated with Remdesivir and Convalescent Plasma for Covid-19 at the Largest Transplant Center in the United States
Miami Transplant Institute, Jackson Health System, Miami, FL
*Purpose: Solid organ transplant recipients (SOTr) are at high risk for severe disease with SARS-CoV-2. Data on efficacy of potential treatment options and long-term outcomes…2021 American Transplant Congress
Longitudinal Antibody Response and Viral Loads in Covid-infected Organ Transplant Recipients
*Purpose: The full spectrum of COVID-19 disease and the impact of disease severity on antibody response and viral shedding dynamics in transplant patients is unclear.…2021 American Transplant Congress
Leflunomide Therapy for Treatment of Bk Viremia in Pediatric Kidney Transplant Recipients
*Purpose: BK viremia (BKV) after kidney transplantation (KT) poses significant risk for BK virus-associated nephropathy (BKVN) and impacts graft survival. Conventional treatment involves reduction of…2021 American Transplant Congress
Influence of Induction Therapy and Antiretroviral Regimen on Outcomes in HIV Positive Renal Transplant Recipients
*Purpose: Transplantation of HIV+ individuals has become more common over the past decade with increasing data supporting good outcomes. Questions remain regarding the impact of…2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution…2021 American Transplant Congress
The Use of Hcv Nat+ Organs in Hcv Negative Recipients with On-site Specialty Pharmacy Services: A Win for the Patient, the Transplant Center, and Society?
Medical University of South Carolina, Charleston, SC
*Purpose: Use of HCV AB positive organs (HCV AB+) with active viremia (NAT+) relies on appropriate and timely use of direct acting antiviral therapies (DAA).…2021 American Transplant Congress
Influence of Immunosuppressant Management on Mortality in Kidney Transplant Recipients Hospitalized with COVID-19
Mount Sinai Hospital, New York, NY
*Purpose: Kidney transplant recipients are thought to be at high risk for mortality from COVID-19 due to the necessity for chronic immunosuppressive therapy to prevent…2021 American Transplant Congress
Current Practices for Management and Treatment of COVID-19 in Immunocompromised Adults: A Survey of Institutions
*Purpose: The optimal testing strategy for solid organ transplantation (SOT) donor and recipient evaluation, as well as treatment for COVID-19 is unknown. We assessed the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 14
- Next Page »